Literature DB >> 17915566

Muscular dystrophy, incurability, eugenics.

Y Rideau1, F Rideau.   

Abstract

The medical entity "muscular dystrophy" has been the object of a recent opinion campaign aimed at promoting a law in favour of euthanasia. This disease has become, in the eyes of the public, a media model of a particularly severe and incurable disease. This very widespread statement does not correspond to reality as far as concerns the life of these patients, to the condition that they have benefited from a very useful and fully provided empirical treatment. As already seen, the hope for life has already doubled, without clear limits. The idea of inducing an interruption when at death's door, as long as a systematic prevention prior to birth, does not conform with the motivated opinion of the majority of patients consulted. On the contrary, the dogma of incurability may lead to dramatic individual consequences which should be stressed, from a medical viewpoint, on account of the unacceptable risks of social injustice or eugenics that this would imply.

Entities:  

Mesh:

Year:  2007        PMID: 17915566      PMCID: PMC2949327     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  17 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Management of progressive muscular dystrophy in childhood.

Authors:  P J VIGNOS; G E SPENCER; K C ARCHIBALD
Journal:  JAMA       Date:  1963-04-13       Impact factor: 56.272

3.  Research against incurability. Treatment of lethal neuromuscular diseases focused on Duchenne Muscular Dystrophy.

Authors:  Y Rideau; L Politano
Journal:  Acta Myol       Date:  2004-12

4.  Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia.

Authors:  S Ward; M Chatwin; S Heather; A K Simonds
Journal:  Thorax       Date:  2005-12       Impact factor: 9.139

5.  Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy.

Authors:  A Hahn; J R Bach; A Delaubier; A Renardel-Irani; C Guillou; Y Rideau
Journal:  Arch Phys Med Rehabil       Date:  1997-01       Impact factor: 3.966

6.  [Treatment of myopathy at Duchenne de Boulogne: results obtained at specialized center].

Authors:  J Demos; A Laqueche; D Fourquet
Journal:  Arch Fr Pediatr       Date:  1968-02

7.  Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy.

Authors:  J R Bach; Y Ishikawa; H Kim
Journal:  Chest       Date:  1997-10       Impact factor: 9.410

8.  Misconceptions about nasal ventilation.

Authors:  Y Rideau; A Delaubier; C Guillou; A Renardel-Irani
Journal:  Lancet       Date:  1994-09-10       Impact factor: 79.321

9.  Long-term nasal intermittent positive pressure ventilation in advanced Duchenne's muscular dystrophy.

Authors:  A Vianello; M Bevilacqua; V Salvador; C Cardaioli; E Vincenti
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

10.  Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs.

Authors:  Maurilio Sampaolesi; Stephane Blot; Giuseppe D'Antona; Nicolas Granger; Rossana Tonlorenzi; Anna Innocenzi; Paolo Mognol; Jean-Lauren Thibaud; Beatriz G Galvez; Ines Barthélémy; Laura Perani; Sara Mantero; Maria Guttinger; Orietta Pansarasa; Chiara Rinaldi; M Gabriella Cusella De Angelis; Yvan Torrente; Claudio Bordignon; Roberto Bottinelli; Giulio Cossu
Journal:  Nature       Date:  2006-11-15       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.